Rixon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rixon

Quick Facts

Property Description
Active ingredient Risperidone
Form Tablets, oral solution, injectable suspension
Pharmacological class Atypical Antipsychotic (Second-Generation Neuroleptic)
General purpose Stabilization of thought and mood
Origin Synthetic compound

What Type of Medication is Rixon (Risperidone)?

Rixon is a prescription-only medication whose active ingredient is Risperidone, classified as an atypical antipsychotic agent. This class is often referred to as a second-generation neuroleptic. Risperidone is a synthetic compound that functions as a powerful psychotropic drug intended to modulate activity within the central nervous system. The core chemical structure of Risperidone is a benzisoxazole derivative. The use of atypical agents like Rixon is clinically recognized for providing a balanced approach to managing severe mental conditions where regulation of complex brain signaling is required.

The classification of Rixon as an atypical antipsychotic is defined by its distinct mechanism involving antagonism at multiple receptors, which characterizes its specific pharmacological role among similar medicines. This means that Rixon operates differently from older drugs in its category by influencing more than one chemical messenger in the brain, a quality observed across diverse patient groups.

Composition and Available Forms of Rixon

The medication is a single-ingredient product composed exclusively of the active ingredient Risperidone, alongside various excipients necessary for drug delivery. The primary drug forms include standard tablets, orally disintegrating tablets, and a liquid oral solution for day-to-day oral use. For long-term administration, an extended-release injectable suspension is available, which is administered via the intramuscular route. The orally disintegrating form is often favored in clinical practice for patients who may have difficulty swallowing solid medication, offering a practical convenience for consistent adherence.

General Purpose and Mechanism Summary

The general therapeutic purpose of Rixon is to help restore critical chemical balance in the brain, thereby promoting stability in thought processes and emotional regulation. This stabilization is achieved because Risperidone acts as an antagonist at both Dopamine D2 receptors and Serotonin 5HT2 receptors. This dual, or "atypical," mechanism principle differentiates it from agents that focus predominantly on a single pathway. By regulating these fundamental signaling pathways, Rixon contributes to improving overall cognitive coherence and emotional equilibrium, which is the foundational benefit in scenarios involving disorganized thought.

Regulatory References

  1. Risperidone - StatPearls - NCBI Bookshelf

What side effects are possible with Rixon?

Possible Side Effects and Safety Information

The official safety profile of Rixon (Risperidone) is documented through clinical data and classified by regulatory agencies according to frequency and body system. This framework separates common, expected adverse reactions from serious, less frequent safety concerns.

Frequency and Organ Systems

The most frequently reported adverse reactions are classified as Very Common (ge 1/10 patients) and involve the Nervous System and Metabolism [accessdata.fda.gov]. These include Parkinsonism (a type of movement disorder), headache, sedation or somnolence, and weight increased.

Reactions classified as Common (ge 1/100 to < 1/10 patients) extend to other body systems, including dizziness, akathisia (restlessness), tremor, and dystonia. Gastrointestinal effects often reported are constipation, dyspepsia, and nausea [dailymed.nlm.nih.gov].

The medicine is known to cause Metabolic Changes, such as hyperglycemia, and to elevate the hormone prolactin, resulting in hyperprolactinemia, an effect that can persist during chronic administration.

Serious Adverse Reactions and Safety Constraints

The prescribing information contains warnings regarding serious conditions. Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD) are rare but clinically significant syndromes reported with the use of antipsychotics [accessdata.fda.gov].

Population-Specific Warnings address a critical safety point: in elderly patients with dementia-related psychosis, treatment is associated with an increased risk of mortality and cerebrovascular adverse events (e.g., stroke) [ema.europa.eu]. Due to this finding, the medication is not approved for use in this specific population. Additionally, orthostatic hypotension may occur, specifically during initial dose titration of the oral form [accessdata.fda.gov].

Overdose and Emergency Response

The official regulatory documents state that an overdose of Rixon (Risperidone) results from an exaggeration of the drug's known pharmacological effects, primarily impacting the Central Nervous System (CNS) and Cardiovascular System (CVS). Documented overdose presentations include drowsiness, sedation, tachycardia (rapid heart rate), hypotension (low blood pressure), and extrapyramidal symptoms (involuntary movements). More severe, life-threatening outcomes reported in overdose cases include convulsions, coma, and significant cardiac abnormalities such as a prolonged QT interval on an ECG.

When an overdose is suspected, immediate medical attention must be sought. Official guidance requires contacting emergency services and a certified poison control center. Because no specific antidote is known for Rixon, management is strictly symptomatic and supportive. Treatment involves close medical supervision and monitoring, ensuring adequate airway, oxygenation, and ventilation. Continuous monitoring of cardiac rhythm and vital signs is essential until recovery. Supportive procedures, such as the use of activated charcoal, may be considered if appropriate. A specific note exists regarding the risk of severe extrapyramidal symptoms in the paediatric population following accidental ingestion.

Therapeutic Uses of Rixon

Rixon (Risperidone) is an atypical antipsychotic commonly used across multiple clinical contexts to provide symptomatic relief and support general well-being. It is utilized across conditions characterized by periods of heightened symptoms. The primary therapeutic applications include the management of Schizophrenia, treatment of acute manic or mixed episodes associated with Bipolar I Disorder, and addressing irritability linked to Autistic Disorder.


Quick Fact: Symptomatic Relief Domains

The medication is applied in addressing symptoms like hallucinations and delusions, which are the most noticeable symptoms of psychosis.


The core benefit of this medication is its role in managing symptom clusters that may become intense or disruptive, such as periods of mood fluctuation or aggression. Applied in clinical settings that involve acute or unstable symptom patterns, it is commonly used to help patients cope more steadily with these shifts. This use provides support that helps ease the overall symptom burden during these periods of heightened symptoms.

Regulatory References

  1. FDA Label for Risperidone

Eligibility and Restrictions for Use

Eligibility: Official Regulatory Profile

Rixon (risperidone) is strictly limited to specific patient populations defined by health regulatory agencies. Eligibility is determined by age, indication, and pre-existing medical conditions.

Eligibility Scope Status Based on Official Labeling
Populations Contraindicated Patients with known hypersensitivity to risperidone, paliperidone, or any formulation component.
Age-Related Eligibility Use is not established in children under 5 years of age for any approved use. Approved minimum ages vary by indication (e.g., ge 5 years for Autistic Irritability; ge 13 years for Schizophrenia).
Condition-Specific Exclusion Not approved for treating psychosis related to dementia in elderly patients, a population with an officially recognized increased risk of death.
Organ Impairment Patients with severe renal or hepatic impairment are eligible but require a mandated reduced starting dose and slower dose titration.
Pregnancy and Lactation Use during pregnancy is restricted to cases where benefit outweighs risk. The drug is excreted in human milk, requiring a decision to discontinue nursing or the medication.

Eligibility is primarily established by confirming the patient meets the minimum age for the specific approved condition, and is immediately prohibited if an absolute contraindication, such as a known allergy, is present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for Rixon (Risperidone) is defined by pharmacokinetic changes in drug exposure and clinically relevant pharmacodynamic additive or antagonistic effects.

Classification Official Regulatory Information
Medicinal product categories with documented interactions: Strong CYP2D6 inhibitors, CYP3A4 inducers, P-glycoprotein (P-gp) inhibitors, centrally-acting drugs, drugs with hypotensive effects, drugs known to prolong the QTc interval, and dopamine agonists.
Specific interacting medicines (if explicitly listed): Fluoxetine and Paroxetine (increase plasma concentration); Carbamazepine and Rifampicin (decrease plasma concentrations); Levodopa (antagonized effects).

Official Interaction Statements:

  • Co-administration with strong CYP2D6 inhibitors (like Fluoxetine) is documented to increase the plasma concentration of risperidone and its active fraction, resulting from a pharmacokinetic interaction through enzyme inhibition.
  • Co-administration with strong CYP3A4 inducers (like Carbamazepine) is officially noted to decrease the plasma concentrations of the risperidone active antipsychotic fraction.
  • The combination with centrally-acting drugs and alcohol is officially noted to potentially cause additive Central Nervous System (CNS) depressant effects, and alcohol must be avoided.
  • Rixon may antagonize the effects of Levodopa and other dopamine agonists, a documented pharmacodynamic interaction.
  • Co-administration with drugs known to prolong the QT interval (e.g., Pimozide, Thioridazine) is restricted due to a documented cardiovascular risk.

Interaction-Context Constraints:

  • The absorption of oral risperidone is not clinically affected by food.
  • Severe Renal or Hepatic Impairment may increase the potential for pharmacokinetic interactions due to slower drug clearance.

The overall interaction structure in regulatory documents specifies constraints on co-administration based on the potential to alter drug exposure or heighten specific physiological risks, such as additive sedation or QTc prolongation.

Mechanism of Action

How Rixon Works: Mechanism of Action

Rixon acts by intervening within specific pathways that modulate renal electrolyte transport and peripheral vascular resistance. The resulting physiological consequence is a decrease in the systemic pressure exerted by circulating volume on the vascular walls.


Modulating Electrolyte Transport in the Kidneys

Rixon primarily acts as an inhibitor of the sodium-chloride cotransporter (NCC) protein found in the distal convoluted tubules of the kidney. This action blocks the reabsorption of sodium ( Na^+) and chloride ( Cl^-) ions, causing them to be excreted with water in the urine. This process of enhanced salt and water loss results in a net reduction in the body's total fluid volume.


Influencing Circulatory Volume and Vascular Resistance

The reduced retention of salt and water influences fluid dynamics, leading directly to a decrease in circulating fluid volume. The reduction in circulating fluid volume exerts less physical pressure on the inner walls of the vasculature. Furthermore, the drug is associated with a mechanism that causes the blood vessels to relax and widen (vasodilation). These combined mechanistic effects influence the circulatory system, resulting in decreased peripheral resistance and a reduction in the hydrostatic pressure of the blood.

Dosage and Administration Information

How Rixon (Risperidone) is Used: Official Administration Guidelines

Administration of Rixon involves detailed protocols concerning dosage, route, and scheduling. The medicine is administered via the oral route (tablets, solution, or orally disintegrating tablets) for daily use, or as a long-acting intramuscular (IM) or subcutaneous (SC) injection. Injectable formulations are strictly restricted from being given intravenously (IV).


Dosage and Frequency Patterns

Dosing specifies ranges that vary by indication and formulation. For adults with Schizophrenia, oral treatment typically begins at 2 mg daily, with a usual maintenance range of 4–8 mg daily. For Bipolar Mania, the maintenance dose often falls between 1–6 mg daily. Dose adjustments, or titration, for oral forms should occur slowly, at intervals of at least 24 hours.

Long-acting injectable forms are administered less frequently. The IM formulation is typically given every two weeks, while SC formulations may be given monthly or every two months. When initiating the IM injection, oral Rixon must be continued for the first three weeks to ensure therapeutic levels are achieved, and IM dose increases must not occur more often than every four weeks.


Contextual Use and Adjustments

Oral Rixon can be taken with or without food. The oral solution is compatible with liquids like water, coffee, or low-fat milk but must not be mixed with cola or tea. Specific administration rules exist for patient populations: older adults and patients with severe renal or hepatic impairment require a lower initial dose of 0.5 mg twice daily with a significantly slower titration schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Rixon (Risperidone)

Evidence for use in Schizophrenia

The core evidence concerning Rixon for Schizophrenia was derived from randomized controlled trials (RCTs). These short-term trials were used in research exploring how symptoms change over time during periods of increased symptom activity, typically over a period of four to twelve weeks. These studies monitored the severity of symptoms such as delusions and hallucinations using standardized rating scales, with the aim of researching short-term symptom changes in adults and adolescents.

Beyond the initial short-term research, studies have also explored long-term outcomes through maintenance RCTs and observational settings evaluating daily-life functioning. Research examined whether a continued approach was associated with patterns of symptom recurrence, with observation periods described as lasting up to two years. The long-acting injectable forms of Rixon were also evaluated in observational studies to provide data on patterns of use outside of clinical trials.

Evidence for use in Bipolar I Disorder (Manic or Mixed Episodes)

Rixon was studied for Bipolar I Disorder in the context of acute manic or mixed episodes, which are conditions involving periods of heightened symptoms. The primary research consists of short-term, placebo-controlled RCTs lasting a few weeks. These trials research examined changes in outcomes describing episodic or acute changes in mood stability and symptom intensity. Rixon was evaluated in these studies both as a treatment on its own (monotherapy) and as an add-on therapy alongside mood stabilizers.

Evidence for addressing Irritability in Autistic Disorder

The evidence base for Rixon in Autistic Disorder is focused specifically on the outcomes linked to inflammatory or irritative states such as aggression, severe temper tantrums, and self-injury. The main research has involved short-term, controlled trials that studies monitored these specific behaviors in children and adolescents, which are outcomes capturing phases of heightened symptom activity. Critically, these studies research examined only the associated behavioral issues, providing limited information about Rixon’s relationship to the core social or communication outcomes related to the disorder.

What is Still Uncertain About Rixon

The research landscape highlights several areas where data are still emerging or where evidence is limited. The most consistent research limitation is that the follow-up durations were limited in many controlled trials, particularly concerning functional and quality-of-life outcomes reflecting daily functioning or activity level. Furthermore, subgroup findings are uncertain, as controlled studies are typically designed to test a broad population, meaning the specific response patterns in groups defined by particular co-existing conditions or demographic factors are not fully established. The findings describe group patterns, not personal outcomes, and the research does not provide individual predictions about whether an individual will respond similarly.

Key Studies & References Efficacy and Safety of Risperidone Interventions in Children and Adolescents with Autism Spectrum Disorder (Meta-analysis of irritability treatment)

Frequently Asked Questions (FAQ)

Common questions about Rixon (FAQ)


Q: Is it normal to feel no difference in the first few days of taking Rixon?

A: The onset of Rixon’s effects may take time to develop. Regulatory documents indicate that for the medicine to reach its effective concentration in the body, it may require a few weeks. The official protocol notes that when initiating the injectable form, a transition period of several weeks is outlined to ensure therapeutic levels are achieved.


Q: What signs should a person watch for that might indicate a severe side effect?

A: Official warnings document serious but rare conditions associated with this class of medication. For instance, Neuroleptic Malignant Syndrome (NMS) may involve symptoms like high fever, severe muscle rigidity, and changes in consciousness. Another noted condition, Tardive Dyskinesia (TD), involves involuntary, uncontrolled movements. The occurrence of these unusual or severe signs necessitates prompt medical evaluation.


Q: Is it okay to use Rixon with common pain relievers like Tylenol (acetaminophen)?

A: The official interaction profile lists specific drug categories and medicines that alter Rixon's concentration in the body. While common pain relievers like acetaminophen are not typically listed among these interacting drugs, there are no specific warnings against this combination documented in the primary regulatory information.


Q: Are there any specific foods that should be avoided when taking Rixon?

A: According to the official product information, the absorption of oral Rixon is not clinically affected by food, meaning it can be taken with or without meals. However, the liquid oral solution is noted to be incompatible with certain liquids like cola or tea and should not be mixed with them.


Q: Is Rixon considered a maintenance treatment or a short-term treatment?

A: Official guidelines and research indicate that Rixon is often used as a maintenance treatment for certain conditions like Schizophrenia. For these indications, the dosing protocols define a typical maintenance range to support long-term stability. Studies have also explored the use of the medicine through maintenance clinical trials.


Q: Is Rixon known for causing withdrawal-like symptoms if stopped?

A: The official documentation does not use the specific term 'withdrawal symptoms' but includes a warning against abruptly stopping the medication. This warning notes that sudden cessation may increase the risk of a return of symptoms or a relapse for the conditions the medicine is being used to manage.


Q: How long does Rixon stay in the system after the last use?

A: The time it takes for a substance to be cleared from the system is measured by its half-life. The official pharmacokinetics data indicates that the combined active components of Rixon (the medicine and its main active metabolite) have an elimination half-life of approximately 20 to 23 hours in most patients.


Q: What are the general long-term expectations for using Rixon?

A: When used long-term, official warnings describe that the risk of certain serious conditions, such as movement disorders like Tardive Dyskinesia (TD), is associated with increasing with the duration of treatment and total cumulative dose. For this reason, long-term use requires medical monitoring for these potential metabolic changes and movement issues, as outlined in the regulatory documentation.


Q: Does Rixon affect liver function tests?

A: Official reports indicate that Rixon has been associated with elevations in serum aminotransferase levels. These are specific markers that are measured in liver function tests (LFTs). These changes are often reported as mild and transient in the regulatory data.


Q: Can Rixon be taken with multivitamins or herbal supplements like St. John's Wort?

A: The regulatory documents explicitly advise that Rixon should not be used concurrently with the herbal supplement St. John’s Wort. This combination may reduce the amount of Rixon in the bloodstream, potentially resulting in reduced effectiveness.


Q: Does Rixon interact with blood pressure or heart medications?

A: Official interaction guidance notes a risk when Rixon is co-administered with blood pressure medicines (antihypertensive agents). This combination may result in additive hypotensive effects (a combined blood pressure lowering effect). Rixon is also restricted for use with medicines that prolong the QT interval due to a documented cardiovascular risk.


Q: Can Rixon be used by children or adolescents?

A: Rixon is approved for use in certain pediatric populations, but the approved minimum age varies depending on the condition being addressed. Regulatory documentation specifies different minimum ages for conditions like Autistic Irritability (as low as 5 years) and Schizophrenia (as low as 13 years).


Q: Are there known risks for people with diabetes taking Rixon?

A: Rixon is associated with potential metabolic changes and has been linked to the development of hyperglycemia (high blood sugar). Official warnings indicate that it can also worsen pre-existing diabetes. Official guidance indicates that medical monitoring for changes in blood glucose levels may be necessary.


Q: Does Rixon affect fertility in men or women?

A: Rixon is known to elevate the hormone prolactin, resulting in hyperprolactinemia, an effect that may persist during chronic use. This elevation may influence reproductive function by inhibiting ovulation in female patients and may also potentially affect fertility in male patients, as noted in the adverse reaction profile.


Q: Are there long-term studies available for Rixon use beyond a year?

A: Research has included the exploration of long-term outcomes and patterns of symptom recurrence in maintenance clinical trials and observational studies. These studies have documented outcomes over periods described as lasting up to two years for certain indications, confirming that long-term data is available within this scope.


Q: What information is available regarding Rixon's potential for overdose?

A: Official patient information notes that in cases of potential overdose, there is no specific antidote or treatment available to reverse the effects of Rixon.


Q: Does Rixon affect sleep patterns or energy levels?

A: Sedation or somnolence (drowsiness) is documented as a Very Common adverse reaction in the official product information. However, some patients have also reported other sleep disturbances, such as difficulty falling or staying asleep, suggesting a range of effects on sleep patterns.


Q: How should a person manage mild, common side effects while taking Rixon?

A: Official patient materials often include general, non-directive suggestions for common side effect management, such as strategies mentioned to address constipation or dizziness (orthostatic hypotension).


How should Rixon be stored and disposed of?

The official regulatory requirements for Rixon storage focus on maintaining product stability and ensuring safety.

Storage Conditions

Rixon (Risperidone) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication requires protection from light, moisture, and excessive heat, and it is explicitly required that liquid formulations do not freeze.

Keep the medicine in its original container, ensuring it remains tightly closed. The Orally Disintegrating Tablets (ODT) must be used immediately after removal from the blister pack. The oral solution must be discarded if unused 3 months after first opening.

Safety and Disposal

It is mandatory to keep Rixon out of the sight and reach of children and pets. For disposal, patients must ask a healthcare professional or pharmacist how to discard any unused or outdated medication, as regulatory guidance advises against throwing medicines away via wastewater or general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rixon found in:

A-Z Index: